MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
// Wei-Yu Chen 1, 2, * , Shih-Yang Liu 3, * , Yung-Sheng Chang 4 , Juan Juan Yin 5 , Hsiu-lien Yeh 6 , Tarek H. Mouhieddine 7 , Ola Hadadeh 7 , Wassim Abou-Kheir 7 , Yen-Nien Liu 4 1 Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 2 Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 3 Department of Acupuncture and Manipulation, College of International Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China 4 Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan 5 Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 6 Institute of Information System and Applications, National Tsing Hua University, HsinChu, Taiwan 7 Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon * These authors contributed equally to this work Correspondence to: Wassim Abou-Kheir, e-mail: wa12@aub.edu.lb Yen-Nien Liu, e-mail: liuy@tmu.edu.tw Keywords: Prostate cancer, bone metastasis, miR-34a, TCF7, BIRC5 Received: August 15, 2014 Accepted: November 02, 2014 Published: November 25, 2014 ABSTRACT Aberrant activation of Ras and WNT signaling are key events that have been shown to be up-regulated in prostate cancer that has metastasized to the bone. However, the regulatory mechanism of combinatorial Ras and WNT signaling in advanced prostate cancer is still unclear. TCF7 , a WNT signaling-related gene, has been implicated as a critical factor in bone metastasis, and here we show that TCF7 is a direct target of miR-34a. In samples of prostate cancer patients, miR-34a levels are inversely correlated with TCF7 expression and a WNT dependent gene signature. Ectopic miR-34a expression inhibited bone metastasis and reduced cancer cell proliferation in a Ras-dependent xenograft model. We demonstrate that miR-34a can directly interfere with the gene expression of the anti-proliferative BIRC5, by targeting BIRC5 3’UTR. Importantly, BIRC5 overexpression was sufficient to reconstitute anti-apoptotic signaling in cells expressing high levels of miR-34a. In prostate cancer patients, we found that BIRC5 levels were positively correlated with a Ras signaling signature expression. Our data show that the bone metastasis and anti-apoptotic effects found in Ras signaling-activated prostate cancer cells require miR-34a deficiency, which in turn aids in cell survival by activating the WNT and anti-apoptotic signaling pathways thereby inducing TCF7 and BIRC5 expressions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Polakis, P. (2000) · Genes & Development · doi:10.1101/gad.14.15.1837 · Cited by 3,183 · cited 1×
“The development of cancer via aberrant WNT signaling most likely results from stabilized β-catenin which in turn mediates inappropriate gene activation [14].”
BackgroundTargeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · cited 1×
“Moreover, up-regulation of Rasmediated signaling cascades may reflect up-regulations in various pathways such as the mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/ AKT cascades [7, 8], and WNT signaling [9].”
BackgroundTransactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010 · cited 2×
“Importantly, miR-34a is an important factor of the p53 network where miR-34a is a direct transcriptional target of p53 [23, 39, 40].”
BackgroundRAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 2×
“The presence of Ras mutations as a cause of resistance to apoptosis in various cancers brought a major challenge in the treatment of metastasis [25].”
BackgroundThe Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
The miR-34 family in cancer and apoptosis
Hermeking, H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.56 · Cited by 1,236 · cited 3×
“In support of prostate cancer tumorigenesis, the microRNA-34 (miR-34) family has shown anti-proliferative and apoptotic roles and its inactivation has been reported in malignant prostate cancer [22, 23].”
Background
Cited by
miRNA nanotherapeutics for cancer
Ganju, A., Khan, S., Hafeez, B. B., Behrman, S. W., Yallapu, M. M., Chauhan, S. C., & Jaggi, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.014 · Cited by 298
The crosstalk between microRNAs and the Wnt/β-catenin signaling pathway in cancer
Peng, Y., Zhang, X., Feng, X., Fan, X., & Jin, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.12923 · Cited by 149
The comprehensive landscape of miR-34a in cancer research
Li, S., Wei, X., He, J., Cao, Q., Du, D., Zhan, X., Zeng, Y., Yuan, S., & Sun, L. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09973-3 · Cited by 84
Sex-specific transcriptional rewiring in the brain of Alzheimer’s disease patients
Santiago, J. A., Quinn, J. P., & Potashkin, J. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1009368 · Cited by 16
“TCF7 is involved in prostate cancer (Chen et al., 2015; Siu et al., 2017), and it is highly expressed in immune cells in atherosclerosis plaques (Ma et al.”
Background
Metadata
- Authors
- Chen, W.-Y., Liu, S.-Y., Chang, Y.-S., Juan Yin, J., Yeh, H.-L., Mouhieddine, T. H., Hadadeh, O., Abou-Kheir, W., & Liu, Y.-N.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-11-25
- Volume
- 6
- Issue
- 1
- Pages
- 441-457
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1576913910
- Cited by
- 100
- References
- 10
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.